Developing an inhaled antibody therapy for Respiratory Syncytial Virus (RSV)
Official title: GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus
Funded at Inhalon Biopharma, INC. · NIH-11084445 · Data updated 2026-11-12
This study is testing a new inhaled treatment called IN-002 for Respiratory Syncytial Virus (RSV) to help infants, young children, and vulnerable adults breathe easier at home and avoid hospital visits.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Inhalon Biopharma, INC. NIH-funded |
| Lab location | 1 site (Morrisville, UNITED STATES) |
| Project start | June 1, 2023 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $608,832 |
| NIH project number | 5SB1AI179368-03 |
| Project ID | NIH-11084445 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include infants and young children at risk for RSV, as well as immune-compromised adults and the elderly.
✕Less likely to help
Patients who are not at risk for RSV or who do not have respiratory illnesses may not benefit from this research.
What this research studies
This research focuses on creating a new inhaled therapy designed to treat Respiratory Syncytial Virus (RSV), which is a leading cause of severe respiratory illness in infants and young children, as well as in immune-compromised adults and the elderly. The therapy, known as IN-002, is a monoclonal antibody that targets the virus directly in the airways, where RSV spreads. Patients would use a hand-held device to inhale the treatment at home, potentially providing a more effective way to neutralize the virus and prevent hospitalization. The research involves manufacturing the therapy under Good Manufacturing Practices (GMP) and filing for an Investigational New Drug (IND) application to begin clinical trials.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from RSV, significantly reducing hospitalizations and improving health outcomes.
How similar studies have gone: While there have been various antiviral therapies for respiratory viruses, this specific inhaled antibody approach for RSV is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Inhalon Biopharma, INC.
Morrisville, United States Active
Researchers
- Principal investigator: Hutchins, Jeff T — Inhalon Biopharma, INC.
- Study coordinator: Hutchins, Jeff T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.